LT3250210T - Kompozicijos ir būdai, skirti gydyti cns sutrikimus - Google Patents

Kompozicijos ir būdai, skirti gydyti cns sutrikimus

Info

Publication number
LT3250210T
LT3250210T LTEP16743932.2T LT16743932T LT3250210T LT 3250210 T LT3250210 T LT 3250210T LT 16743932 T LT16743932 T LT 16743932T LT 3250210 T LT3250210 T LT 3250210T
Authority
LT
Lithuania
Prior art keywords
compositions
treatment
methods
cns disorders
cns
Prior art date
Application number
LTEP16743932.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Albert Jean Robichaud
Gabriel Martinez Botella
Francesco G. Salituro
Boyd L. Harrison
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Publication of LT3250210T publication Critical patent/LT3250210T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16743932.2T 2015-01-26 2016-01-26 Kompozicijos ir būdai, skirti gydyti cns sutrikimus LT3250210T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107776P 2015-01-26 2015-01-26
US201562144789P 2015-04-08 2015-04-08
PCT/US2016/014835 WO2016123056A1 (en) 2015-01-26 2016-01-26 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
LT3250210T true LT3250210T (lt) 2021-04-12

Family

ID=56544215

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16743932.2T LT3250210T (lt) 2015-01-26 2016-01-26 Kompozicijos ir būdai, skirti gydyti cns sutrikimus

Country Status (15)

Country Link
US (2) US10426837B2 (enExample)
EP (1) EP3250210B1 (enExample)
JP (2) JP6745274B2 (enExample)
CY (1) CY1124113T1 (enExample)
DK (1) DK3250210T3 (enExample)
ES (1) ES2857082T3 (enExample)
HR (1) HRP20210344T1 (enExample)
HU (1) HUE054092T2 (enExample)
LT (1) LT3250210T (enExample)
PL (1) PL3250210T3 (enExample)
PT (1) PT3250210T (enExample)
RS (1) RS61530B1 (enExample)
SI (1) SI3250210T1 (enExample)
SM (1) SMT202100113T1 (enExample)
WO (1) WO2016123056A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
TR201901745T4 (tr) 2013-04-17 2019-03-21 Sage Therapeutics Inc 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
RU2754534C2 (ru) 2013-07-19 2021-09-03 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их использование
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TW202426002A (zh) 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3481845T3 (da) 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CA3034262A1 (en) 2016-08-23 2018-03-01 Sage Therapeutics, Inc. A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid
EP4484440A3 (en) 2017-12-08 2025-03-26 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
BR112022019085A2 (pt) 2020-03-25 2023-01-31 Sage Therapeutics Inc Uso de agentes para tratamento de condições respiratórias
CN113968886B (zh) * 2021-11-15 2022-12-13 湖南科瑞生物制药股份有限公司 一种17-甲酸甾体化合物的制备方法
WO2024197317A2 (en) * 2023-03-23 2024-09-26 Emory University Neurosteroids and prodrugs thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) * 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1436324A (en) 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
WO1993005786A1 (en) 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
KR100338287B1 (ko) 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO1996003421A1 (en) 1994-07-21 1996-02-08 Pharmacia & Upjohn Company Neurologically active aminosteroids
GEP20002033B (en) 1994-11-23 2000-04-10 Cocensys Inc Us Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor
ES2235187T3 (es) 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
IL146230A0 (en) 1999-04-29 2002-07-25 Purdue Pharma Ltd 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
ES2243442T3 (es) * 2000-02-18 2005-12-01 Taiho Pharmaceutical Company Limited Procedimiento de preparacion de derivados esteroides.
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
JP2004518637A (ja) 2000-11-03 2004-06-24 ワシントン・ユニバーシティ 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
DE602004024966D1 (de) 2003-03-24 2010-02-25 Sterix Ltd Oestrogenderivate als steroid sulphatase inhibitoren
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
EP1689767A1 (en) 2003-11-24 2006-08-16 Merck & Co., Inc. Estrogen receptor modulators
US20090118248A1 (en) 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP1807118B8 (en) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
PT2168585E (pt) 2005-06-09 2012-03-05 Euro Celtique Sa Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
AU2008265898B2 (en) 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US20130303500A1 (en) 2010-07-30 2013-11-14 Medexis S.A. Compounds and methods for treating neoplasia
WO2012083090A2 (en) 2010-12-15 2012-06-21 Harbor Biosciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
EP2675822A4 (en) 2011-02-15 2014-07-30 Socpra Sciences Et Génie S E C STEROID ALKALOIDS AND THEIR USE AS ANTIMICROBIAL AGENTS AGAINST MICROORGANISMS WITH ELECTRON TRANSPORT FAILURE AND AS MICROBIAL AGENT EXHAUSTERS AGAINST PATHOGENIC BACTERIA
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2987866B1 (en) 2011-03-23 2017-12-06 Etsuro Ito Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
CA2843436A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
EP4245369A3 (en) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2013192097A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2916846B1 (en) 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP6542127B2 (ja) 2012-12-18 2019-07-10 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
TR201901745T4 (tr) 2013-04-17 2019-03-21 Sage Therapeutics Inc 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
RU2754534C2 (ru) 2013-07-19 2021-09-03 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их использование
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE050028T2 (hu) 2014-05-29 2021-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
TW202426002A (zh) 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
AU2016321254A1 (en) 2015-09-08 2018-04-05 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
MA43284A (fr) 2015-11-20 2018-09-26 Sage Therapeutics Inc Composés et leurs méthodes d'utilisation
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
DK3481845T3 (da) 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CA3034262A1 (en) 2016-08-23 2018-03-01 Sage Therapeutics, Inc. A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
MX2020001732A (es) 2017-08-31 2020-03-20 Takeda Pharmaceuticals Co Tratamiento de las afecciones del sistema nervioso central.
IL303250A (en) 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
JP7312169B2 (ja) 2017-11-10 2023-07-20 マリナス ファーマシューティカルズ インコーポレイテッド 遺伝性てんかん性障害の処置に使用するガナキソロン
CN112823164A (zh) 2018-05-04 2021-05-18 阿克罗斯制药公司 神经甾体衍生物和其用途

Also Published As

Publication number Publication date
SI3250210T1 (sl) 2021-07-30
HUE054092T2 (hu) 2021-08-30
PL3250210T3 (pl) 2021-07-26
US11147877B2 (en) 2021-10-19
RS61530B1 (sr) 2021-04-29
JP2018502891A (ja) 2018-02-01
WO2016123056A1 (en) 2016-08-04
JP2020189848A (ja) 2020-11-26
US20200246459A1 (en) 2020-08-06
EP3250210A4 (en) 2018-08-22
SMT202100113T1 (it) 2021-05-07
PT3250210T (pt) 2021-03-26
CY1124113T1 (el) 2022-05-27
EP3250210B1 (en) 2020-12-02
ES2857082T3 (es) 2021-09-28
US20170319695A1 (en) 2017-11-09
HRP20210344T1 (hr) 2021-05-14
JP6745274B2 (ja) 2020-08-26
DK3250210T3 (da) 2021-03-08
US10426837B2 (en) 2019-10-01
EP3250210A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
LT3250210T (lt) Kompozicijos ir būdai, skirti gydyti cns sutrikimus
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
LT3224269T (lt) Kompozicijos ir būdai, skirti cns sutrikimams gydyti
IL285151A (en) Methods of treating fgf21-associated disorders
LT3496739T (lt) Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
LT3206497T (lt) Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui
IL247452A0 (en) Compounds for treatment of complement mediated disorders
SI3206493T1 (sl) Sestavki in metode za zdravljenje CNS motenj
LT3600270T (lt) Junginiai ir kompozicijos hematologiniams sutrikimams gydyti
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
EP3280420A4 (en) Compositions and methods for treating cns disorders
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL259674B (en) Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders
HK1242518A1 (en) Compositions and methods for treating cns disorders